Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin + Sitagliptin vs Individual Agents in T2DM (VERTIS FACTORIAL)
NCT02099110Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Apr 2014; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02099110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099110.